A Phase 4 interventional study of Paracetamol 1000 mg and Paracetamol 650 mg in Post-surgical Dental Pain, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-04-29.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.
Among the 55 studies in Toothache with a site in United States, this one is the 8th largest by enrollment of the 51 interventional ones that give a count, is one of 10 that started in 2009, is one of 10 in phase 4, and was the 16th registered.
143 studies on the registry are indexed under Toothache; 29 are open to participants now.
Browse Toothache studies →7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 23 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 86 across 124 interventional studies indexed under Toothache.
Median enrollment 193 across the 51 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 55 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
GlaxoSmithKline has 6 studies filed under Toothache — fewer than ten, so there is no comparison to draw.
5 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT07945431South Rampart Pharma, Inc.A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction | 2027-02-28 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline will be conducting this trial to compare analgesic efficacy of paracetamol 1000 mg vs 650 mg. The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be approximately 18 weeks. Each subject will have to come to the clinic for three visits (Screening, Treatment and Follow up visits).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Paracetamol 1000mg
Drug: Paracetamol 1000 mg
Paracetamol 650 mg
Drug: Paracetamol 650 mg
Placebo
Drug: Placebo
Paracetamol 1000mg
Paracetamol 650 mg
Placebo
Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours)
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]
Time frame: Every two hours from Baseline to 6 hours post dose
Time to Confirmed First Perceptible Relief
Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.
Time frame: Baseline to 6 hours post dose
Time to Onset of Meaningful Pain Relief
Participants recorded the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.
Time frame: Baseline to 6 hours post dose
Time to Start Using Rescue Medication
Median time of use of rescue medication by participants.
Time frame: Baseline to 6 hours post dose
Percentage of Participants Who Took Rescue Medication at 2 Hours
Percentage of participants who received rescue medication at different time points post dose.
Time frame: Baseline to 2 hours post dose
Percentage of Participants Who Took Rescue Medication at 6 Hours
Percentage of participants who received rescue medication at different time points post dose.
Time frame: Baseline to 6 hours post dose
SPRID at 2 Hours
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief
Time frame: Every two hours from baseline to 2 hours post dose
SPRID at 4 Hours
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief
Time frame: Every two hours from baseline to 4 hours post dose
Total Pain Relief Score (TOTPAR) at 2 Hours
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
Time frame: Every two hours from baseline to 2 hours post dose
TOTPAR at 4 Hours
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
Time frame: Every two hours from baseline to 4 hours post dose
TOTPAR at 6 Hours
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
Time frame: Every two hours from baseline to 6 hours post dose
Sum of Pain Intensity Difference (SPID) Scores at 2 Hours
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
Time frame: Every two hours from baseline to 2 hours post dose
SPID Scores at 4 Hours
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
Time frame: Every two hours from baseline to 4 hours post dose
SPID Scores at 6 Hours
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
Time frame: Every two hours from baseline to 6 hours post dose
Participants Global Assessment to Response to Treatment (PGART)
PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.
Time frame: Baseline to 6 hours post dose
Participants were recruited at the clinical site.
| Milestone | Paracetamol Caplet 1000 Milligrams (mg) | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Started | 163 | 158 | 80 |
| Completed | 157 | 155 | 80 |
| Not completed | 6 | 3 | 0 |
| Withdrew: Lost to follow-up | 5 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -5.8 (least pain relief) to 40.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief\]
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Sum of Pain Relief and Pain Intensity Differences From 0 to 6 Hours (SPRID 6 Hours) | 16.08 ± 10.68 | 12.42 ± 9.89 | 4.63 ± 8.82 |
Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.
| minutes | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Time to Confirmed First Perceptible Relief | 54.72 ± 104.911 | 69.67 ± 120.501 | 225.70 ± 162.884 |
Participants recorded the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.
| minutes | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Time to Onset of Meaningful Pain Relief | 70.53 ± 101.474 | 88.16 ± 115.955 | 247.14 ± 143.028 |
Median time of use of rescue medication by participants.
| minutes | Paracetamol Caplet 1000 mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Time to Start Using Rescue Medication | 360.00 (124.00 to 360.00) | 314.00 (123.00 to 360.00) | 131.00 (115.00 to 360.00) |
Percentage of participants who received rescue medication at different time points post dose.
| Percentage of participants | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Percentage of Participants Who Took Rescue Medication at 2 Hours | 0.00 | 0.00 | 1.30 |
Percentage of participants who received rescue medication at different time points post dose.
| Percentage of participants | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Percentage of Participants Who Took Rescue Medication at 6 Hours | 44.20 | 51.90 | 70.00 |
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -1.8 (least pain relief) to 12.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| SPRID at 2 Hours | 6.49 ± 3.11 | 5.57 ± 2.94 | 1.55 ± 2.45 |
SPRID:Sum of Pain Intensity Difference (SPID) and Total Pain Relief (TOTPAR) at each post-dosing time-point. SPRID score ranged from -3.8 (least pain relief) to 26.3 (highest pain relief). SPID and TOTPAR were calculated as weighted sums of Pain Intensity Differences (PID) and Pain Relief Scores (PRS) at each measurement time, respectively. PID was derived by subtracting the pain severity score at a given post-dosing time-point from the baseline \[pain severity score range:0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain using a 4-point categorical Verbal Rating Scale (VRS)\]. If the subject rated pain intensity as 2 or 3, pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from baseline pain scores. PRS was assessed on 5-point categorical pain relief rating scale \[0-no relief, 1-little relief, 2-some relief, 3-a lot of relief, 4-complete relief
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| SPRID at 4 Hours | 12.09 ± 6.93 | 9.45 ± 6.19 | 3.00 ± 5.27 |
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Total Pain Relief Score (TOTPAR) at 2 Hours | 4.31 ± 1.88 | 3.80 ± 1.89 | 1.36 ± 1.59 |
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| TOTPAR at 4 Hours | 8.21 ± 4.10 | 6.64 ± 3.97 | 2.79 ± 3.46 |
TOTPAR was calculated as sum of products of pain relief (PR) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Higher score indicated greater pain relief. TOTPARt = ∑PR x (timet - timet-1). PR score was assessed at each of the above time-points based on a 5-point categorical scale \[0-no relief, 1-little relief, 2-meaningful relief, 3-a lot of relief, 4-complete relief\].
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| TOTPAR at 6 Hours | 11.06 ± 6.41 | 8.83 ± 6.30 | 4.29 ± 5.80 |
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Sum of Pain Intensity Difference (SPID) Scores at 2 Hours | 2.17 ± 1.37 | 1.77 ± 1.20 | 0.19 ± 1.03 |
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| SPID Scores at 4 Hours | 3.88 ± 3.06 | 2.81 ± 2.52 | 0.20 ± 2.13 |
SPID was calculated as sum of products of Pain Intensity Differences (PID) at a given time-point (t) with the time-interval from that time-point to the previous time-point (t-1). The time-intervals used were 0-15, 15-30, 30-45, 45-60, 60-90, 90-120, 120-240, 240-300 and 300-360. Positive and higher scores indicate greater reduction in pain. SPIDt = ∑PID x (timet - timet-1) Pain Intensity was assessed at baseline and at each time-point based on a 4-point categorical Verbal Rating Scale (VRS) scale: 0-no pain, 1-mild pain, 2-moderate pain, 3-severe pain. If the subject rated pain intensity as "2" or "3", pain was assessed using a 100 mm Visual Analog Scale (VAS) \[0 (no pain), 100 (worst pain)\]. VAS scores were converted into PID scores by subtracting them from pain scores taken at baseline.
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| SPID Scores at 6 Hours | 5.02 ± 4.63 | 3.59 ± 4.01 | 0.34 ± 3.51 |
PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.
| Score on a scale | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| Participants Global Assessment to Response to Treatment (PGART) | 2.20 ± 1.13 | 1.80 ± 1.18 | 0.80 ± 1.05 |
Collected over All adverse events encountered or spontaneously reported following administration of any investigational product, or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paracetamol Caplet 1000mg | — | 0/163 (0%) | 28/163 (17.2%) |
| Paracetamol Caplet 650 mg | — | 0/158 (0%) | 28/158 (17.7%) |
| Placebo Caplet | — | 0/80 (0%) | 18/80 (22.5%) |
| Event | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet |
|---|---|---|---|
| NauseaGastrointestinal disorders | 17/163 | 17/158 | 7/80 |
| HeadacheNervous system disorders | 4/163 | 6/158 | 7/80 |
| VomitingGastrointestinal disorders | 7/163 | 5/158 | 4/80 |
| Age, Continuous(Years) | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet | Total |
|---|---|---|---|---|
| Mean | 19.7 ± 2.26 | 20.4 ± 2.81 | 20.6 ± 2.76 | 20.2 ± 2.61 |
| Sex: Female, Male(Participants) | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet | Total |
|---|---|---|---|---|
| Female | 102 | 104 | 56 | 262 |
| Male | 61 | 54 | 24 | 139 |
| Number of participants with pain severity score measured on a rating scale(Participants) | Paracetamol Caplet 1000mg | Paracetamol Caplet 650 mg | Placebo Caplet | Total |
|---|---|---|---|---|
| Moderate | 109 | 106 | 53 | 268 |
| Severe | 54 | 52 | 27 | 133 |
The record gives a start of Nov 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen